Floatz logo

Duvelisib

Leukemia

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

View all 50

Same molecule, other indications

Duvelisib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
60 / 100
View asset →
follicular lymphomaDormant
B
Indicative ·
56 / 100
View asset →
indolent B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →